Zhejiang Cancer Hospital

This Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to s…

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …

This study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment.…

This early-phase trial tests whether umbilical cord blood cells can safely help people with chronic radiation enteritis, a painful gut condition caused by cancer radiation therapy. Ten adults who have had pelvic or abdominal radiation will receive three weekly infusions of these …

This early-stage trial tests whether umbilical cord blood cells can safely treat lung damage caused by radiation therapy for cancer. Ten adults who have not improved with standard care will receive three weekly infusions of these cells. The main goal is to check safety and see if…

This phase 2 trial tests a new approach for patients with a specific type of mid-low rectal cancer (pMMR/MSS). Participants receive a short course of radiation followed by six cycles of the immunotherapy drug ivonescimab. The goal is to see if this combination can make the cancer…

This study looks at whether pieces of tumor DNA and HPV DNA circulating in the blood can predict if cervical cancer will return after successful first-line treatment. Researchers will collect blood samples over time from 60 patients whose cancer has gone into complete remission. …

This observational study will follow 300 premenopausal women with HR-positive early breast cancer who are already receiving ovarian function suppression (OFS) therapy as part of their routine care. Researchers want to see how many patients stop OFS within two years and why, and w…